Hi @Tradergimp , and if you look back at where the conversation started it was in response to a poster saying that it would be less dilutionary to cancel the rights issue and go with a placement to a cornerstone investor, which is mathematically incorrect as everyone other than the cornerstone is diluted by this process.
So every time you have a placement to sophisticated investors or cornerstone everyone whinges about being diluted by the sophisticated investor, in rights issues you don't get diluted but you have to put your share of the money in or you get diluted. Basically it is up to you to decide whether to put money in or not.
Problem with rights issue is the time they take and the fact that SP can often fall below rights price, so why take them up when you can buy them on market cheaper. Current TON predicament is one example, but don't have to look far to see other recent examples of this.
So it may be better to do a placement but it is certainly more dilutionary to existing shareholders who don't get to participate.
- Forums
- ASX - By Stock
- TON
- Ann: Trading Halt
Ann: Trading Halt, page-97
-
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TON (ASX) to my watchlist
|
|||||
Last
1.1¢ |
Change
0.002(22.2%) |
Mkt cap ! $17.25M |
Open | High | Low | Value | Volume |
0.9¢ | 1.1¢ | 0.9¢ | $5.503K | 537.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 171722 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 491367 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 171722 | 0.011 |
2 | 273406 | 0.010 |
5 | 1389930 | 0.009 |
8 | 2070529 | 0.008 |
7 | 1742974 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 491367 | 5 |
0.013 | 1538461 | 1 |
0.014 | 200000 | 2 |
0.015 | 1333333 | 1 |
0.018 | 166666 | 1 |
Last trade - 15.26pm 15/07/2024 (20 minute delay) ? |
Featured News
TON (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online